CXCR4 and infection: There is a risk that pharmacologic inhibition of CXCR4 could disrupt immune homeostasis and mobilise hematopoietic stem cells (HSCs) from the bone marrow niche with a subsequent increase in the risk of infection or ectopic off-target organ effects [150].